|
Lyon, France
January 30, 2001
Aventis
CropScience, one of the leading crop protection and crop production companies,
has reached agreements for the divestiture of three crop protection
product businesses to several Third Parties. These divestments are part of the Company 's portfolio streamlining
programme and are another step in the process which aims to simplify the
Aventis CropScience product portfolio and to focus on the new, more
profitable products.
The sales contracts cover the global businesses including the manufacture, registration
packages, formulations, trade marks and know how.
Bifenox, a range of herbicides on the market since about 20 years
for use in cereals markets mainly in Europe, brand names Bifenix ®, Foxpro ®, Foxtril ®, and Modown ®, were sold to the
German company Feinchemie Schwebda, Eschwege. In 2000 the Bifenox sales
reached about 12 million Euro. Bifenox businesses in Japan, Korea and
Taiwan are excluded from the deal. Manufacturing will be transferred as of
2002.
Chlormephos, an insecticide range of products known as Dotan ® was
sold to Calliope, Noguères near Pau, France. Main markets for example in maize are France, Spain, Greece and Italy. They
represented sales of about 2 Million Euro in 2000.
Dodine (Doguadine), a fungicide for use in fruit trees, known as
Syllit® with significant volumes in the USA, was sold to Chimac Agriphar,
Liège, Belgium. In 2000 sales amounted to about 3 million Euro. Syllit® is
registered in USA, Europe and other important apple-producing countries.
Some local Aventis CropScience organisations will keep distribution
rights for the divested products, but the company will terminate
any other involvement in the divested assets. The management of the
compounds has been taken over by the new owners with immediate effect. The parties involved decided not to
disclose the price of the transactions.
These three divestitures follow the sale of the global carbetamide
and dimefuron herbicide businesses announced in August 2000 and the guazatine and clofentezine businesses
announced two weeks ago.
For more information on Aventis visit our Web Site http://www.aventis.com
Company news release
N3286 |
